180 related articles for article (PubMed ID: 37449762)
1. First Generation of a Modular Interoperable Closed-Loop System for Automated Insulin Delivery in Patients With Type 1 Diabetes: Lessons From Trials and Real-Life Data.
Benhamou PY; Adenis A; Lablanche S; Franc S; Amadou C; Penfornis A; Kariyawasam D; Beltrand J; Charpentier G
J Diabetes Sci Technol; 2023 Nov; 17(6):1433-1439. PubMed ID: 37449762
[TBL] [Abstract][Full Text] [Related]
2. One-year real-world performance of the DBLG1 closed-loop system: Data from 3706 adult users with type 1 diabetes in Germany.
Benhamou PY; Adenis A; Lebbad H; Tourki Y; Heredia MB; Gehr B; Franc S; Charpentier G
Diabetes Obes Metab; 2023 Jun; 25(6):1607-1613. PubMed ID: 36751978
[TBL] [Abstract][Full Text] [Related]
3. Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial.
Benhamou PY; Franc S; Reznik Y; Thivolet C; Schaepelynck P; Renard E; Guerci B; Chaillous L; Lukas-Croisier C; Jeandidier N; Hanaire H; Borot S; Doron M; Jallon P; Xhaard I; Melki V; Meyer L; Delemer B; Guillouche M; Schoumacker-Ley L; Farret A; Raccah D; Lablanche S; Joubert M; Penfornis A; Charpentier G;
Lancet Digit Health; 2019 May; 1(1):e17-e25. PubMed ID: 33323237
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, Safety, and Satisfaction with the Accu-Chek Insight with Diabeloop Closed-Loop System in Subjects with Type 1 Diabetes: A Multicenter Real-World Study.
Chico A; Navas de Solís S; Lainez M; Rius F; Cuesta M
Diabetes Technol Ther; 2023 Apr; 25(4):242-249. PubMed ID: 36724301
[No Abstract] [Full Text] [Related]
5. Efficacy of a Hybrid Closed-Loop Solution in Patients With Excessive Time in Hypoglycaemia: A Post Hoc Analysis of Trials With DBLG1 System.
Benhamou PY; Adenis A; Tourki Y; Pou S; Madrolle S; Franc S; Kariyawasam D; Beltrand J; Klonoff DC; Charpentier G
J Diabetes Sci Technol; 2024 Mar; 18(2):372-379. PubMed ID: 36172702
[TBL] [Abstract][Full Text] [Related]
6. Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial.
Kariyawasam D; Morin C; Casteels K; Le Tallec C; Sfez A; Godot C; Huneker E; Garrec N; Benhamou PY; Polak M; Charpentier G; Franc S; Beltrand J
Lancet Digit Health; 2022 Mar; 4(3):e158-e168. PubMed ID: 35216750
[TBL] [Abstract][Full Text] [Related]
7. Safety and Glycemic Outcomes During the MiniMed
Pihoker C; Shulman DI; Forlenza GP; Kaiserman KB; Sherr JL; Thrasher JR; Buckingham BA; Kipnes MS; Bode BW; Carlson AL; Lee SW; Latif K; Liljenquist DR; Slover RH; Dai Z; Niu F; Shin J; Jonkers RAM; Roy A; Grosman B; Vella M; Cordero TL; McVean J; Rhinehart AS; Vigersky RA;
Diabetes Technol Ther; 2023 Nov; 25(11):755-764. PubMed ID: 37782145
[No Abstract] [Full Text] [Related]
8. Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial.
Messer LH; Buckingham BA; Cogen F; Daniels M; Forlenza G; Jafri RZ; Mauras N; Muir A; Wadwa RP; White PC; Russell SJ; Damiano ER; El-Khatib FH; Ruedy KJ; Balliro CA; Li Z; Marak MC; Calhoun P; Beck RW
Diabetes Technol Ther; 2022 Oct; 24(10):712-725. PubMed ID: 36173237
[No Abstract] [Full Text] [Related]
9. No more hypoglycaemia on days with physical activity and unrestricted diet when using a closed-loop system for 12 weeks: A post hoc secondary analysis of the multicentre, randomized controlled Diabeloop WP7 trial.
Franc S; Benhamou PY; Borot S; Chaillous L; Delemer B; Doron M; Guerci B; Hanaire H; Huneker E; Jeandidier N; Amadou C; Renard E; Reznik Y; Schaepelynck P; Simon C; Thivolet C; Thomas C; Hannaert P; Charpentier G
Diabetes Obes Metab; 2021 Sep; 23(9):2170-2176. PubMed ID: 34009725
[TBL] [Abstract][Full Text] [Related]
10. Hybrid Closed-Loop Control with Ultrarapid Lispro Compared with Standard Insulin Aspart and Faster Insulin Aspart: An In Silico Study.
Lachal S; Tourki Y; Franc S; Huneker E; Charpentier G; Benhamou PY
J Diabetes Sci Technol; 2023 Jan; 17(1):176-185. PubMed ID: 34658265
[TBL] [Abstract][Full Text] [Related]
11. Real-world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system.
Grassi B; Gómez AM; Calliari LE; Franco D; Raggio M; Riera F; Castro M; McVean J; van den Heuvel T; Arrieta A; Castañeda J; Cohen O
Diabetes Obes Metab; 2023 Jun; 25(6):1688-1697. PubMed ID: 36789699
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes.
Breton MD; Kanapka LG; Beck RW; Ekhlaspour L; Forlenza GP; Cengiz E; Schoelwer M; Ruedy KJ; Jost E; Carria L; Emory E; Hsu LJ; Oliveri M; Kollman CC; Dokken BB; Weinzimer SA; DeBoer MD; Buckingham BA; Cherñavvsky D; Wadwa RP;
N Engl J Med; 2020 Aug; 383(9):836-845. PubMed ID: 32846062
[TBL] [Abstract][Full Text] [Related]
13. Safety and performance of a hybrid closed-loop insulin delivery system with carbohydrate suggestion in adults with type 1 diabetes prone to hypoglycemia.
Mesa A; Beneyto A; Martín-SanJosé JF; Viaplana J; Bondia J; Vehí J; Conget I; Giménez M
Diabetes Res Clin Pract; 2023 Nov; 205():110956. PubMed ID: 37844798
[TBL] [Abstract][Full Text] [Related]
14. Predictors of time in target glucose range in real-world users of the MiniMed 780G system.
Castañeda J; Mathieu C; Aanstoot HJ; Arrieta A; Da Silva J; Shin J; Cohen O
Diabetes Obes Metab; 2022 Nov; 24(11):2212-2221. PubMed ID: 35791621
[TBL] [Abstract][Full Text] [Related]
15. Extended Use of an Open-Source Automated Insulin Delivery System in Children and Adults with Type 1 Diabetes: The 24-Week Continuation Phase Following the CREATE Randomized Controlled Trial.
Burnside MJ; Lewis DM; Crocket HR; Meier RA; Williman JA; Sanders OJ; Jefferies CA; Faherty AM; Paul RG; Lever CS; Price SKJ; Frewen CM; Jones SD; Gunn TC; Lampey C; Wheeler BJ; de Bock MI
Diabetes Technol Ther; 2023 Apr; 25(4):250-259. PubMed ID: 36763345
[No Abstract] [Full Text] [Related]
16. Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance.
Ly TT; Weinzimer SA; Maahs DM; Sherr JL; Roy A; Grosman B; Cantwell M; Kurtz N; Carria L; Messer L; von Eyben R; Buckingham BA
Pediatr Diabetes; 2017 Aug; 18(5):348-355. PubMed ID: 27191182
[TBL] [Abstract][Full Text] [Related]
17. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial.
Tsoukas MA; Majdpour D; Yale JF; Fathi AE; Garfield N; Rutkowski J; Rene J; Legault L; Haidar A
Lancet Digit Health; 2021 Nov; 3(11):e723-e732. PubMed ID: 34580055
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Meal Anticipation for Improving Fully Automated Insulin Delivery in Adults With Type 1 Diabetes.
Garcia-Tirado J; Colmegna P; Villard O; Diaz JL; Esquivel-Zuniga R; Koravi CLK; Barnett CL; Oliveri MC; Fuller M; Brown SA; DeBoer MD; Breton MD
Diabetes Care; 2023 Sep; 46(9):1652-1658. PubMed ID: 37478323
[TBL] [Abstract][Full Text] [Related]
19. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
[TBL] [Abstract][Full Text] [Related]
20. Glycemic Outcomes During Real-World Hybrid Closed-Loop System Use by Individuals With Type 1 Diabetes in the United States.
Arunachalum S; Velado K; Vigersky RA; Cordero TL
J Diabetes Sci Technol; 2023 Jul; 17(4):951-958. PubMed ID: 35414272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
